01 December 2020
Coulter Partners secures Chief Executive Officer for ObsEva
Coulter Partners was delighted to partner with ObsEva SA (NASDAQ: OBSV / SIX: OBSN) to secure the appointment of Brian O’Callaghan as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will succeed Dr Ernest Loumaye and be proposed for election on ObsEva’s Board of Directors at the next company AGM. ObsEva SA is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health.
Please refer to ObsEva’s press release published on November 9th 2020: ObsEva appoints Brian O’Callaghan as CEO
Related
-
Events
Bio€quity Europe 2025
12 May 2025 – 14 May 2025
-
Thought Leadership
Necessarily Different: a continuous global study of the work styles and leadership impact of digital health CEOs and Founders
26 February 2024
-
Company News
LSX World Congress conference with Justine McIlroy, Client Partner
12 May 2023
-
Press Releases
Coulter Partners places Vice President of Intellectual Property at Amphista Therapeutics
09 March 2023